PhD from the department of Bioengineering and Therapeutic Sciences at UCSF, with a research focus in genomics, pharmacokinetics and pharmacometrics. Sirj was a Discovery Fellow at UCSF with 4+ years of industry experience at Genentech and Pfizer. His passion lies in bringing genomics and advanced analytics to the forefront of healthcare. Read more about his work at sirjgoswami.com.
PharmD, PhD with over 30+ publications in clinical pharmacology. Ron is also a software engineer and has developed software for applied modeling & simulation used by >50 pharmaceutical companies and the FDA. After various research positions at leading universities, Ron is now our Chief Scientific Officer.
Bioengineer with 5+ years of experience as a pharmacometrics researcher at Genentech leading PK/PD analytics for various drug candidates in early and late stage clinical trials including regulatory filings. Ranvir is interested in applying next generation software applications and data analytics to enhance therapeutic effectiveness of drug treatment.
Software architect with 10+ years experience in cloud software architecture. Lena is joining from Salesforce where she worked on UI, mobile, and machine learning. Prior to Salesforce, Lena worked at IBM building hardware management tools. Lena also holds an MSc in Science & Technology commercialization and is passionate about advancing the state of IT in health care.
MBA from Harvard Business School. David previously oversaw international product launches for industry-leading medical device and diagnostics companies including Stryker, IDEXX, and Acelity. David is excited to bring his business acumen to bear on the exciting field of precision medicine.
Distributed systems architect with 20+ years experience, Alan, a former VP at Morgan Stanley, is a startup veteran who has held integral engineering roles across fintech, consumer internet/mobile and digital health. Alan holds an MSc in Software Engineering and enjoys building technologies that are grounded in improving the lives of others.
Vikram is joining InsightRX with 5+ years of experience as as engineer specializing in building sophisticated DevOps and automation tools for major technology companies. He is a born and bred Tar Heel and is excited to apply his expertise to elevate the state of healthcare informatics.
Tedmund is joining after an undergraduate career in healthcare research and analytics. He has managed business development for us at the TMCx accelerator, and is now building new features in the platform and handling FDA design control. He is fascinated of the role that artifical intelligence will play in shaping the future of healthcare.
Dr. Boyle is a translational scientist with research interests that include pediatric cancer therapeutics, pharmacokinetics, pharmacodynamics, pharmacogenomics, and clinical trial design. The majority of her research resides within the complex setting of hematopoietic cell transplantation (HCT) and is focused around chemotherapeutic and immunosuppressive agents used in the preparative regimens of pediatric HCT. Specifically, Dr. Boyle studies how covariates such as age, renal function, or genetic variants involved in drug metabolism or distribution may influence drug clearance in the pediatric HCT population.
Before joining UF, Dr. Lesko worked nearly 20 years in the Food and Drug Administration’s Center for Drug Evaluation and Research as the Director of the Office of Clinical Pharmacology. He has also published more than 200 peer-reviewed scientific publications and is a frequent invited national and international speaker in clinical pharmacology, personalized medicine, pharmacometrics and systems pharmacology. His research interests include drug development and regulatory science, quantitative clinical pharmacology and pharmacogenomics.
Dr. Savic's research uses computational methods to study the dynamic interplay between disease progression, drug and biomarker response across relevant scales (molecule, cell, tissue, organ & whole body) in order to determine causal links underlying variability in (safety and efficacy) clinical outcomes. Her goal is to determine the optimal dosage, timing, and duration of therapeutic regimens and ultimately develop precise, personalized treatments.